Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin
NCT00766025
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
CYP2C19 Poor
Extensive Metabolizers
Interventions
DRUG:
Rosuvastatin Calcium
Sponsor
AstraZeneca